<?xml version="1.0" encoding='utf-8' ?>
<nspnews type="text">
<version>v8.0</version>
<date>2025-12-17 21:53:58</date>
<action>I</action>
<registdate>2025-12-17 20:27:09</registdate>
<modifydate>2025-12-17 20:30:16</modifydate>
<publishdate>2025-12-17 21:53:51</publishdate>
<embargo>N</embargo>
<newsid>793412</newsid>
<orgid>793219</orgid>
<language>EN</language>
<category1>20</category1>
<category2>2001</category2>
<category1_name>기업</category1_name>
<category2_name>중기/벤처/기타</category2_name>
<statusID>1</statusID>
<saleID>N</saleID>
<formatID>1</formatID>
<typeID>7</typeID>
<newsSubject><![CDATA[Huons, Receiving IND Approval for Phase 1 Clinical Trial of GLP-1 Small Molecule Obesity Treatment]]></newsSubject>
<newsSummary><![CDATA[]]></newsSummary>
<newsTag><![CDATA[Huons,IND Approval,HUC2-676]]></newsTag>
<newsLinks><![CDATA[]]></newsLinks>
<news_prolog><![CDATA[(Seoul=NSP NEWS) =]]></news_prolog>
<news1><![CDATA[Huons has received approval from the Ministry of Food and Drug Safety for the domestic phase 1 clinical trial plan(IND) for HUC2-676, a glucagon-like peptide-1(GLP-1)-based obesity treatment.

HUC2-676 is a low-molecular-weight synthetic peptide derivative of Saxenda Inj., a drug developed by Novo Nordisk and launched in Korea. This clinical trial aims to demonstrate equivalence by comparing the pharmacokinetic characteristics(PK) of HUC2-676 and Saxenda in healthy adults.

For the past two years, Huons has been developing an obesity treatment based on the GLP-1 receptor agonist(GLP-1RA). GLP-1RAs are known to stimulate insulin secretion and suppress glucagon secretion, lowering blood sugar levels. They also act on the hypothalamus in the brain to induce a feeling of satiety.

Huons plans to expand its obesity treatment portfolio beyond existing appetite suppressants like Hutermin Tablets and Pendi Tablets, as well as HUC2-676, through diverse R&D efforts, aiming to leap forward as a leader in the obesity market.

“We are aiming to obtain product approval by securing quality equivalence between HUC2-676 and Saxenda, as well as securing non-clinical data and phase 1 clinical trial data,” said the Vice President of Research and Development at Huons. “We will provide a new option for obesity treatment by developing a small-molecule synthetic peptide that has secured equivalence with existing biopharmaceuticals.”]]></news1>
<news2_title><![CDATA[]]></news2_title>
<news2><![CDATA[]]></news2>
<news3><![CDATA[]]></news3>
<news4_title><![CDATA[]]></news4_title>
<news4><![CDATA[]]></news4>
<news5_title><![CDATA[]]></news5_title>
<news5><![CDATA[]]></news5>
<news_epilog_info><![CDATA[]]></news_epilog_info>
<news_epilog_byline><![CDATA[By Soon-ki Lee(s8789@nspna.com) and Songyi Jeong(qu225577@nspna.com)]]></news_epilog_byline>
<news_epilog><![CDATA[ⓒNSP News Agency·NSP TV. All rights reserved. Prohibits using to train AI models.]]></news_epilog>
<imageL><![CDATA[https://file.nspna.com/news/2025/12/17/20251217203016_793412_0.png]]></imageL>
<imageP><![CDATA[https://file.nspna.com/news/2025/12/17/photo_20251217203016_793412_0.png]]></imageP>
<image1><![CDATA[https://file.nspna.com/news/2025/12/17/20251217203016_793412_1.png]]></image1>
<image2><![CDATA[]]></image2>
<image3><![CDATA[]]></image3>
<image4><![CDATA[]]></image4>
<image5><![CDATA[]]></image5>
<image1_place><![CDATA[c]]></image1_place>
<image2_place><![CDATA[c]]></image2_place>
<image3_place><![CDATA[c]]></image3_place>
<image4_place><![CDATA[c]]></image4_place>
<image5_place><![CDATA[c]]></image5_place>
<image1_text><![CDATA[]]></image1_text>
<image2_text><![CDATA[]]></image2_text>
<image3_text><![CDATA[]]></image3_text>
<image4_text><![CDATA[]]></image4_text>
<image5_text><![CDATA[]]></image5_text>
<image1_source><![CDATA[]]></image1_source>
<image2_source><![CDATA[]]></image2_source>
<image3_source><![CDATA[]]></image3_source>
<image4_source><![CDATA[]]></image4_source>
<image5_source><![CDATA[]]></image5_source>
<vodSite><![CDATA[]]></vodSite>
<vodID><![CDATA[]]></vodID>
<vodTitle><![CDATA[]]></vodTitle>
<vodWidth><![CDATA[]]></vodWidth>
<vodHeight><![CDATA[]]></vodHeight>
<advertorial><![CDATA[]]></advertorial>
<location><![CDATA[Seoul]]></location>
<teamID>110</teamID>
<teamName><![CDATA[국제부]]></teamName>
<writerID>s8789</writerID>
<writerName><![CDATA[Soon-ki Lee]]></writerName>
<writerTitle><![CDATA[Reporter]]></writerTitle>
<writerEmail><![CDATA[s8789@nspna.com]]></writerEmail>
<writerID2>qu225577</writerID2>
<writerName2><![CDATA[Songyi Jeong]]></writerName2>
<writerTitle2><![CDATA[Reporter]]></writerTitle2>
<writerEmail2><![CDATA[qu225577@nspna.com]]></writerEmail2>
<writerID3></writerID3>
<writerName3><![CDATA[]]></writerName3>
<writerTitle3><![CDATA[]]></writerTitle3>
<writerEmail3><![CDATA[]]></writerEmail3>
</nspnews>
